Merit Medical Hosts Medical Education Course on LV Implantation Techniques

Merit Medical hosted a course on LV Lead Implantation Techniques May 4-5. The course was conducted by Seth J. Worley, MD, Director of the Interventional Implant Program at Lancaster General Hospital in Lancaster, Pennsylvania. Dr. Worley is an internationally recognized expert and key opinion leader in the advancement of cardiac resynchronization therapy.

Dr. Worley presented unique approaches to LV lead implantation and techniques designed to help reduce procedure and fluoroscopy time, reduce lead failure rates, and improve lead location.1

In addition to the hands-on training with the unique tools and techniques, Dr. Worley also used the tools in two live cases in which he was able to demonstrate successfully this specialized approach. Each of the eight physicians on hand were able to learn interactively as he described each of the steps in the procedure to the audience through a live video feed and to the physicians who joined him in the procedure room.

When used together, the Worley Advanced System provides the tools and solutions needed to reduce implantation times, gain easier access to the target vessel, and improve chances for successful CRT implantation.1

Worley™ Advanced CSG

Worley™ Advanced LVI

Worley™ Vein Selector

For more information or to register for the next Worley training course, contact your local Merit Medical Sales Representative or visit merit.com.

Nelson Gardner
Business Development Manager

1 Jackson KP, Hegland DD, Frazier-Mills C, Piccini JP, Koontz JI, Atwater BD, Daubert JP, Worley SJ. Impact of using a telescoping-support catheter system for left ventricular lead placement on implant success and procedure time of cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2013 May; 36(5):553-8.

DFINE Announces Commencement Of Clinical Study On Spinal Tumor Ablation With The STAR Tumor Ablation System

San Jose, Calif. and Magdeburg, Germany – June 11, 2014DFINE®, Inc., a market leader in the minimally invasive treatment of spinal diseases, today announced that the first patient has been enrolled in the EU-STAR Clinical Trial. The multi-center trial is the first prospective study to evaluate clinical outcomes in patients receiving treatment with the STAR™ Tumor Ablation System for the palliative treatment of metastatic spinal tumors.

DFINE will enroll 40 patients at five centers in Germany and France. The trial will evaluate pain relief at one month as a primary outcome measure with follow up through six months. Secondary outcome measures include change in function, quality of life and pain medications post-procedure.

“We’ve had very promising results with targeted RF ablation (t-RFA™) to ‘melt’ the tumor followed by RF targeted vertebral augmentation™ (RF-TVA) during the same procedure to repair the damaged vertebrae,” said Dr. Boris Joellenbeck, a principal investigator at The Otto-von-Guericke University Magdeburg in Germany, where the first patient was treated. “Immediately following the procedure, the patient had a significant reduction in pain and increased activity level. We are excited about the many potential benefits of this therapeutic approach for our patients.”

Cancer is a major public health problem throughout the world, with more than 3.4 million new diagnoses each year in Europe alone.1 When cancer is not found early, it can metastasize (spread) to other parts of the body. A spinal tumor is a growth of cells (mass) in or around the vertebra near the spinal cord. It is estimated that 30-40 percent of cancer patients will likely develop metastatic spinal tumors.Many of these tumors also result in fractures of the vertebrae.

“t-RFA and RF-TVA provide an innovative new treatment option for the many patients worldwide who suffer from the debilitating effects of spinal tumors,” said Greg Barrett, Chief Executive Officer of DFINE. “As a company we are committed to building a body of scientific evidence supporting the therapy and are excited to partner with several leading medical centers in Germany and France on this landmark trial.”

To learn more about the EU-STAR clinical trial (ID # NCT02081053), interested parties may contact the study research staff found here: http://www.clinicaltrials.gov/ct2/show/NCT02081053 

About STAR™ Tumor Ablation System

t-RFA with the STAR System does not treat cancer. It is cleared by the FDA for providing palliative treatment (e.g. pain relief) by ablation of metastatic malignant tumors in a vertebral body. For a complete list of indications, risks and contraindications, visit http://www.dfineinc.com/Product-Risk—SpineSTAR

About DFINE, Inc.

DFINE is dedicated to relieving pain and improving the quality of life for patients suffering from spinal diseases through innovative, minimally invasive therapies. The company’s flagship products, the StabiliT® Vertebral Augmentation System and STAR™ Tumor Ablation System, represent generational advancements in the minimally invasive treatment of spinal diseases. DFINE is based in San Jose, Calif. and is a privately held company.

DFINE and StabiliT are registered trademarks and STAR and Targeted Radiofrequency Ablation (t-RFA) are trademarks of DFINE, Inc. [media-contact]

SCAI 2014 Attendees Get Hands On with Merit Medical’s Radial-Specific Products

Attendees were offered hands-on demonstrations of our radial products at the Society for Cardiovascular Angiography and Interventions (SCAI) meeting last week in Las Vegas. We exhibited several products supporting transradial access–the Rad Board® radial arm board and accessories, radial catheters, and the Safeguard Radial™ radial closure device–that generated lots of interest at the booth.

STREAMLINE SET UP FOR RADIAL PROCEDURES
With dedicated, radial-specific arm boards and accessories, cath lab personnel don’t need to use towels to obtain correct arm positioning. The reusable Rad Board fits all cath lab and radiology procedure tables. Visitors at the booth were surprised to learn that there is a section of Xenolite TB embedded in the Rad Board that helps to reduce scatter radiation exposure. See Radiation Scatter Survey Results.

RADIAL-SPECIFIC CATHETERS
We had a vascular model that attendees could use for a hands-on demonstration of our Performa Ultimate™ line of catheters. Merit also has the MIV™ radial ventriculogram pigtail catheter that is designed to angle toward the left coronary cusp to facilitate transradial access.

HEMOSTASIS OF THE RADIAL ARTERY
We demonstrated the Safeguard Radial pressure assisted device by putting it on some attendees. As a result, they learned firsthand how comfortable and convenient it is to get adjustable compression of the radial puncture site.

Attendees at SCAI this year were excited to learn about Merit’s new Think Radial training courses and enjoyed the hands-on demonstrations of our radial-specific products. For more information on our radial product portfolio or upcoming training courses, Contact Us.

Chan Ream
Product Manager

Merit Medical To Exhibit at PICS-AICS 2014 Chicago Symposium

For 16 years, Merit Medical has participated as an exhibitor at the Pediatric and Adult Interventional Cardiac Symposium (PICS-AICS). This year, the symposium will be held at the Marriott Chicago Downtown, June 7-10, 2014.

Merit Medical is committed to supplying purpose-built pediatric products for diagnostic and interventional medicine, particularly for interventional cardiology.

  • The Merit Diagnostic Cardiology FEP Catheter line includes a 3F Pediatric Pigtail Catheter.
  • The Merit Pediatric Judkins Right and Judkins Left Catheters are available with shapes as small as JR 1.5 and JL 1.5.
  • Merit also provides Pediatric Vessel Sizing Catheters.

New to our pediatric product line this year are:

We would like to invite you to stop by Booth 311 to view these products and many others offered by Merit Medical for the Pediatric and Adult Interventional Cardiologist.

For more information about Merit’s pediatric products, Contact Us.

Tami Anderson
Senior Product Manager